NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity, supporting the regulatory advancement of NV-387, a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks.
NV-387 is a unique broad-spectrum antiviral drug that the company plans to develop as a treatment for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. It has also shown effectiveness in animal models for monkeypox (MPox), smallpox, and measles. The company’s other advanced drug candidate, NV-HHV-1, targets all herpesvirus infections including HSV-1 cold sores, HSV-2 genital ulcers, and varicella-zoster virus (VZV) shingles and chickenpox.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials. For more details on the announcements, visit the full press release at https://ibn.fm/uIWWv.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. The company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants. For the latest news and updates relating to NNVC, visit the company’s newsroom at https://ibn.fm/NNVC.
This Orphan Drug Designation marks a significant milestone for NanoViricides, potentially accelerating the development of NV-387 as a treatment for measles, a disease that has seen a resurgence globally. The incentives associated with orphan drug status, such as tax credits for clinical trials, fee waivers, and seven-year market exclusivity upon approval, could reduce development costs and provide a competitive edge.
The broad-spectrum nature of NV-387 underscores its potential to address multiple viral threats, positioning NanoViricides as a key player in antiviral therapeutics. As the company progresses toward Phase II trials, the designation may also facilitate discussions with regulatory agencies and attract potential partners or investors.
With measles outbreaks on the rise in various parts of the world, the need for effective treatments is urgent. NV-387's progress could offer a new therapeutic option for patients, particularly those with compromised immune systems or severe cases. The company's focus on advancing this drug into later-stage clinical trials will be closely watched by the medical and investment communities.
